

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Center for Advancing Translational Sciences; Notice of Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the meeting of the National Center for Advancing Translational Sciences Advisory Council.

The meeting will be open as indicated below, viewing virtually by Webex.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Individuals can register to view and access the meeting by the link below. <https://nih.webex.com/nih/onstage/g.php?MTID=ea58bf69ded4e3ef172feeb063ee9e4e5>.

1. Go to "Event Status" on the left hand side of page, then click "Register". On the registration form, enter your information and then click "Submit" to complete the required registration.

2. You will receive a personalized email with the live event link.

*Name of Committee:* National Center for Advancing Translational Sciences Advisory Council.

*Date:* June 13, 2016.

*Open:* 12:00 p.m. to 2:00 p.m.

*Agenda:* Report from the Institute Director and other staff.

*Place:* National Institutes of Health, NCATS Board Room, 9800 Medical Center Drive, Rockville, MD 20850, (Virtual Meeting).

*Closed:* 2:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, NCATS Board Room, 9800 Medical Center Drive, Rockville, MD 20850, (Virtual Meeting).

*Contact Person:* Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809, [anna.ramseyewing@nih.gov](mailto:anna.ramseyewing@nih.gov).

This notice is being published less than 15 days prior to the meeting due to finalizing the agenda and scheduling of meeting topics.

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5

U.S.C. App.), notice is hereby given of the meeting of the Cures Acceleration Network Review Board.

*Name of Committee:* Cures Acceleration Network Review Board.

*Date:* June 13, 2016.

*Time:* 12:00 p.m. to 2:00 p.m.

*Agenda:* Report from the Institute Director.

*Place:* National Institutes of Health, NCATS Board Room, 9800 Medical Center Drive, Rockville, MD 20850, (Virtual Meeting).

*Contact Person:* Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809, [anna.ramseyewing@nih.gov](mailto:anna.ramseyewing@nih.gov).

This notice is being published less than 15 days prior to the meeting due to finalizing the agenda and scheduling of meeting topics.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: May 23, 2016.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-12500 Filed 5-26-16; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Human Genome Research Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel; ENCODE Characterization.

*Date:* July 7, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Renaissance Arlington Capital View Hotel, 2800, Studio D, South Potomac Ave., Arlington, VA 22202.

*Contact Person:* Keith McKenney, Ph.D., Scientific Review Officer, NHGRI, 5635

Fishers Lane, Suite 4076, Bethesda, MD 20814, 301-594-4280, [mckenneyk@mail.nih.gov](mailto:mckenneyk@mail.nih.gov).

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel; ENCODE DATA.

*Date:* July 14, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crystal City Marriott, Need Rom Room, 1999 Jefferson Davis Highway, Arlington, VA 22202.

*Contact Person:* Lita Proctor, Ph.D., Extramural Research Programs Staff, Program Director, Human Microbiome Project, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, Bethesda, MD 20892, 301 496-4550, [proctorlm@mail.nih.gov](mailto:proctorlm@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: May 20, 2016.

**Sylvia L. Neal,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-12501 Filed 5-26-16; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****Office of the Director, National Institutes of Health; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Recombinant DNA Advisory Committee.

*Date:* June 21-22, 2016.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* The NIH Recombinant DNA Advisory Committee (RAC) will review and discuss selected human gene transfer protocols and related data management activities. In addition, Dr. Carl June (Perelman School of Medicine, Univ. of Pennsylvania) will present the results of findings of his group regarding a rare Chimeric Antigen Receptor (CAR) T cell manufacturing event. For more information, please check the meeting agenda at the OSP Web site, RAC Meeting Page (available at the following URL: <http://osp.od.nih.gov/office-biotechnology-activities/event/2016-06-21-120000-2016-06-210000/rac-meeting>).

Place: National Institutes of Health, Building 35, Conference Room 620/630, 9000 Rockville Pike, Rockville, MD 20852.

Contact Person: Shayla Beckham, Extramural Support Assistant, Office of Science Policy, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892-9606, 301-496-9838, [beckhams@mail.nih.gov](mailto:beckhams@mail.nih.gov).

Information is also available on the Institute's/Center's home page: <http://oba.od.nih.gov/rdna/rdna.html>, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: May 23, 2016.

**Carolyn Baum,**

*Program Specialist, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-12503 Filed 5-26-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Request for Information on the Development of the FY 2018 Trans-NIH Plan for HIV-Related Research

**SUMMARY:** Through this Request for Information (RFI), the Office of AIDS Research (OAR) in the Division of

Program Coordination, Planning, and Strategic Initiatives, National Institutes of Health (NIH) invites feedback from investigators in academia, industry, health care professionals, patient advocates and health advocacy organizations, scientific or professional organizations, federal agencies, and other interested constituents and the community on the development of the fiscal year 2018 Trans-NIH Plan for HIV-Related Research. This plan is designed to identify and articulate possible future directions to maximize benefits of investments in HIV/AIDS research.

**DATES:** The Office of AIDS Research Request for Information is open for public comment for a period of 30 days. Comments must be received by June 27, 2016 to ensure consideration. After the public comment period has closed, the comments received will be considered in a timely manner by the Office of AIDS Research in the Division of Program Coordination, Planning, and Strategic Initiatives.

**ADDRESSES:** Submissions may be electronically to [OAR\\_RFI18@od.nih.gov](mailto:OAR_RFI18@od.nih.gov).

#### FOR FURTHER INFORMATION CONTACT:

Questions about this request for information should be directed to Shoshana Kahana, Ph.D., Office of AIDS Research, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, National Institutes of Health, 5601 Fishers Lane, Bethesda, MD 20892, [OAR\\_RFI18@od.nih.gov](mailto:OAR_RFI18@od.nih.gov), 301-496-0357.

**SUPPLEMENTARY INFORMATION:** OAR oversees and coordinates the conduct and support of all HIV/AIDS research activities at the NIH. The NIH-sponsored HIV/AIDS research program includes both extramural and intramural research, buildings and facilities, research training, and program evaluation and supports a comprehensive portfolio of research representing a broad range of basic, clinical, behavioral, social science, and translational research on HIV/AIDS and its associated coinfections. The NIH HIV/AIDS research program is conducted and supported by nearly all of the NIH Institutes and Centers (ICs).

OAR plans and coordinates research through the development of an annual Trans-NIH Plan for HIV-Related Research (the "Plan") that articulates the overarching HIV/AIDS research priorities and serves as the framework for developing the trans-NIH AIDS research budget. The Plan provides information about the NIH's HIV/AIDS research priorities to the scientific community, Congress, community stakeholders, HIV-affected communities,

and the broad public at large. The fiscal year 2017 Plan was recently distributed on the OAR Web site: ([http://www.oar.nih.gov/strategic\\_plan/fy2017/OARStrategicPlan2017.pdf](http://www.oar.nih.gov/strategic_plan/fy2017/OARStrategicPlan2017.pdf)).

New overarching priorities for HIV/AIDS research for the next three to five years were defined in the NIH Director's Statement of August 12, 2015 (<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>).

High Priority topics of research for support include:

- (1) Reducing the incidence of HIV/AIDS (including the development of a safe and effective vaccine, microbicides, and pre-exposure prophylaxis candidates);
- (2) Developing the next generation of HIV therapies with less toxicity, better safety, and ease of use;
- (3) Identifying strategies to cure AIDS; and
- (4) Improving the prevention and treatment of HIV-associated comorbidities, coinfections, and complications.

There also are three cross-cutting areas associated with these overarching priorities which include:

- (1) Basic research underlying the basic biology of HIV (*e.g.*, transmission and pathogenesis; immune dysfunction and chronic inflammation; host microbiome and genetic determinants);
- (2) Research to reduce health disparities in the incidence of new HIV infections or in treatment outcomes of those living with HIV/AIDS; and
- (3) Research training of the workforce required to conduct high priority HIV/AIDS research.

#### Information Requested

OAR is seeking input on the inclusion of important new and/or emerging areas of scientific investigation to inform the development of the fiscal year 2018 Trans-NIH Plan for HIV-Related Research. The overarching high-priority areas of research as delineated in NOT-15-137 will remain unchanged. OAR would like feedback on those scientific and research opportunities that refine the NIH HIV/AIDS research agenda and optimize the investment of HIV/AIDS research resources to search for critical strategies to prevent, treat, and cure AIDS.

Please provide your perspective on any of the following topics as they relate to the development of the fiscal year 2018 Trans-NIH Plan for HIV-Related Research. Comments can include but are not limited to the following areas:

1. Emerging strategies and technologies related to the development, testing, and production of promising HIV vaccine candidates (active and